Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash.  This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. Nipocalimab gives Janssen the opportunity to reach significantly more patients across many autoimmune disease ...